论文部分内容阅读
目的观察白芍总苷(TGP)联合柳氮磺吡啶(SASP)和甲氨蝶呤(MTX)治疗强直性脊柱炎的临床疗效和安全性。方法将72例强直性脊柱炎患者随机分为对照组和观察组,每组36例。对照组口服甲氨蝶呤和柳氮磺吡啶治疗,观察组在对照组基础上,加服白芍总苷,连续治疗3个月,观察3个月后2组患者的临床指标改善和不良反应发生情况。结果治疗后,2组胸廓扩张度较治疗前增大,晨僵持续时间较治疗前减短,Schober试验、C反应蛋白和红细胞沉降率优于治疗前(P<0.05或P<0.01);观察组各指标改善情况均优于对照组(P<0.05或P<0.01)。观察组不良反应发生率为8.33%,低于对照组的27.78%(P<0.05)。结论白芍总苷联合甲氨蝶呤和柳氮磺吡啶治疗强直性脊柱炎具有良好的疗效,且安全性高。
Objective To observe the clinical efficacy and safety of total glucosides of paeony (TGP) combined with sulfasalazine (SASP) and methotrexate (MTX) in the treatment of ankylosing spondylitis. Methods 72 patients with ankylosing spondylitis were randomly divided into control group and observation group, 36 cases in each group. The control group was treated with methotrexate and sulfasalazine. The observation group was treated with total glucosides of paeony on the basis of the control group for 3 months. The improvement of clinical indexes and adverse reactions were observed in the two groups after 3 months What happened? Results After treatment, the dilatation degree of thorax in both groups increased before treatment and the duration of morning stiffness decreased compared with that before treatment. The Schober test, C-reactive protein and erythrocyte sedimentation rate were better than those before treatment (P <0.05 or P <0.01) The improvement of each index in the group was better than that in the control group (P <0.05 or P <0.01). The incidence of adverse reactions in the observation group was 8.33%, which was lower than that in the control group (27.78%, P <0.05). Conclusion Total glucosides of paeony root combined with methotrexate and sulfasalazine treatment of ankylosing spondylitis has good curative effect and high safety.